Zynerba Pharmaceuticals develops transdermal cannabinoid treatments for patients with high unmet medical needs. Read more

Armando Anido's photo - Chairman & CEO of Zynerba

Chairman & CEO

Armando Anido

CEO Approval Rating





PublicIndependent CompanyNASDAQZYNE









Missing a competitor? Contribute!

Inovio is one of Zynerba's top competitors. Inovio was founded in 1979, and its headquarters is in Plymouth Meeting, Pennsylvania. Like Zynerba, Inovio also works within the Biotechnology sector. Inovio has 237 more employees than Zynerba.

Kite Pharma is Zynerba's #2 rival. Kite Pharma was founded in 2009 in Santa Monica, California. Kite Pharma operates in the Biotechnology industry. Kite Pharma generates $44.9M more revenue than Zynerba.

bluebird bio is a top competitor of Zynerba. bluebird bio is a Public company that was founded in Cambridge, Massachusetts in 1992. bluebird bio is in the Biotechnology field. bluebird bio has 1,188 more employees vs. Zynerba.


Help the Owler community know more

Competitor - 1/1

Is CytImmune a competitor of Zynerba?

Zynerba Quarterly and Annual Revenue

Coming soon for Zynerba!

Annual Revenue

$ < 1M

Zynerba's revenue is the ranked 14th among it's top 10 competitors. The top 10 competitors average 3.6B.

Zynerba Acquisitions

No recent acquisitions found related to Zynerba

Zynerba Funding History

Since Zynerba was founded in 2007, it has participated in 2 rounds of funding. In total Zynerba has raised $55.0M. Zynerba's last funding round was on Aug 2015 for a total of $42.0M





Aug 2015

Sep 2014

Perceptive Advisors LLC

Since Zynerba was founded in 2007, it has participated in 2 rounds of funding. In total Zynerba has raised $55.0M. Zynerba's last funding round was on Aug 2015 for a total of $42.0M

Zynerba Investments

No recent investments found related to Zynerba

Zynerba News

June 4, 2021Markets Insider

Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

DEVON, Pa., June 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leade... See more »
May 26, 2021Markets Insider

Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader... See more »
May 12, 2021Proactive Investors

Zynerba says its fully funded well into 2024; lays out plans for Zygel RECONNECT trial for Fragile X patients

The company reported that cash on hand increased 57% year-over-year from $59.2 million to $93.1 milli... See more »
May 12, 2021Benzinga

Zynerba's Shares Jump on CBD Zygel Trial Plans, Company Reports Cash Until 2024

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 m... See more »
May 5, 2021Proactive Investors

Zynerba receives FDA guidance on confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome

The RECONNECT trial of the transdermal get is designed to evaluate its efficacy and safety in childre... See more »
May 3, 2021Law 360

CBD Co. Zynerba, Investors Seek OK For $4M Settlement Deal

Investors in CBD drugmaker Zynerba Pharmaceuticals have asked a federal judge in Pennsylvania to appr... See more »
April 29, 2021Proactive Investors

Dalrada Financial, ESE Entertainment, Ayurcann Holdings, Predictiv AI, Golden Arrow Resources UPDATE

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires... See more »

Zynerba Press Releases

December 8, 2020GlobalNewswire

Barr Law Group Investigating the Officers and Directors of EQT, ZYNE, NKTR, and FMO; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- National law firm Barr Law Group is investigating the ac... See more »
September 14, 2020GlobeNewswire

Zynerba Pharmaceuticals Provides Update on Recent Milestones

- Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulato... See more »
May 11, 2020GlobeNewswire

Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

Topline Results from Pivotal CONNECT-FX and Phase 2 BRIGHT Trials Expected in the Second Quarter of 2... See more »
December 6, 2019NewMediaWire

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Zynerba Pharmaceuticals, Inc. To Contact The Firm

NEW YORK, NY - (NewMediaWire) - December 06, 2019 - Faruqi & Faruqi, LLP, a leading national securiti... See more »
September 5, 2019GlobeNewswire

Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms

- Preliminary Evidence Shows that CBD May Prove to be Effective in Managing the Spectrum of Behaviora... See more »

Social Media

Zynerba Headquarters

80 W. Lancaster Avenue Suite 300

Devon, Pennsylvania19333


Driving Directions »

Trending Companies

Zynerba Summary



Zynerba Pharmaceuticals develops transdermal cannabinoid treatments for patients with high unmet medical needs. Zynerba was founded in 2007. Zynerba's headquarters is located in Devon, Pennsylvania, USA 19333. It has raised 55.0M in 2 rounds. The late...


Zynerba's Chairman & CEO, Armando Anido, currently has an approval rating of 74%. Zynerba's primary competitors are Inovio, Kite Pharma & bluebird bio.

Frequently Asked Questions about Zynerba

  1. When was Zynerba founded?

    Zynerba was founded in 2007
  2. Who is Zynerba's CEO?

    Zynerba's CEO is Armando Anido
  3. How much revenue does Zynerba generate?

    Zynerba generates $ < 1M in revenue
  4. How much funding does Zynerba have?

    Zynerba has historically raised $55M in funding
  1. Where is Zynerba's headquarters?

    Zynerba's headquarters is in Devon Pennsylvania, USA
  2. How many employees does Zynerba have?

    Zynerba has 25 employees
  3. What sector does Zynerba operate in?

    Zynerba is in Biotechnology
  4. Who are Zynerba's competitors?

    Zynerba's top competitors are Inovio, Kite Pharma, bluebird bio